Fecal Adnab-9 binding as a risk marker for colorectal neoplasia

Cancer Letters

Volumn 235, Issue 1, 2006, Pages 48-52

  Yuan, Mei ^a   Xhang, XiaoPing ^a   Leu, YiaLi ^a   Xu, Yi ^b   Ullah, Nadeem ^b   Lawson, Michael ^c   Tobi, Martin ^b  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Adnab 9; Colonic polyps; Colorectal neoplasia; Monoclonal antibodies

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ADNAB 2; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; BINDING SITE; CANCER RISK; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECTUM POLYP; RISK ASSESSMENT;

ADENOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645895003     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.03.042     Document Type: Article

References (20)

1. Levin B., Smith R.A., Feldman G.E., Colditz G.A., Fletcher R.H., Nadel M., et al. Promoting early detection tests for colorectal carcinoma and adenomatous polyps: a framework for action: the strategic plan of the National Colorectal Cancer Roundtable. Cancer 95 (2002) 1618-1628
2. Winawer S., Fletcher R., Rex D., Bond J., Burt R., Ferrucci J., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124 (2003) 544-560
3. Barkun A.N., Jobin G., Cousineau G., Dube S., Lahaie R., Pare P., et al. The Quebec Association of Gastroenterology position paper on colorectal cancer screening-2003. Can. J. Gastroenterol. 18 (2004) 509-519
4. Gatto N.M., Frucht H., Sundararajan V., Jacobson J.S., Grann V.R., and Neugut A.I. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J. Natl Cancer Inst. 95 (2003) 230-236
5. Newcomb P.A., Norfleet R.G., Storer B.E., Surawicz T.S., and Marcus P.M. Screening sigmoidoscopy and colorectal cancer mortality. J. Natl Cancer Inst. 84 (1992) 1572-1575
6. Ahlquist D.A. Fecal occult blood testing for colorectal cancer. Can we afford to do this?. Gastroenterol. Clin. North Am. 26 (1997) 41-55
7. Bond J.H. Fecal occult blood testing for colorectal cancer. Can we afford not to do this?. Gastroenterol. Clin. North Am. 26 (1997) 57-70
8. Tagore K.S., Levin T.R., and Lawson M.J. The evolution to stool DNA testing for colorectal cancer. Aliment. Pharmacol. Ther. 19 (2004) 1225-1233
9. Song K., Fendrick A.M., and Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 126 (2004) 1270-1279
10. Tobi M., Kaila V., Hassan N., Gallinger S., Fligiel S., Hatfield J., et al. Monoclonal antibody Adnab-9 defines a preneoplastic marker in epithelium at risk for adenocarcinoma of the small intestine. Hum. Pathol. 30 (1999) 467-473
11. Sheikh R., Min B., Yasmeen S., Teplitz R., Tesluk H., Ruebner B.H., et al. Comparison of Ki-67, Adnab-9, p53 immunohistochemical staining, and ploidy with clinical and histological features of severely dysplastic colorectal adenomas. Dig. Dis. Sci. 48 (2003) 223-229
12. Tobi M., Elitsur Y., Moyer M.-P., Halline A., Deutsch M., Nochomovitz L., et al. Mucosal origin and shedding of an early colonic tumor marker defined by Adnab-9 monoclonal antibody. Scand. J. Gastroenterol. 28 (1993) 1025-1034
13. Tobi M., Maliakkal B., Zitron I., Alousi M., Goo R., Nochomovitz L., et al. Adenoma-derived antibody, Adnab-9 recognizes a membrane-bound glycoprotein in colonic tissue and effluent material from patients with colorectal neoplasia. Cancer Lett. 67 (1992) 61-69
14. Tobi M., Prabhu S., Gage R., Orr T., and Lawson M.J. Colorectal cancer risk. The impact of evidence of a field effect of carcinogenesis on blinded diagnosis using an anti-adenoma antibody test performed on colonoscopic effluent. Dig. Dis. Sci. 47 (2002) 317-321
15. Qiao S., Yuan M., Liu Y., Lin X., Zhang X., and Tobi M. Detection of gastric cancer and premalignant lesions by novel marker glycoprotein 87 using monoclonal antibody Adnab-9. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 1095-1099
16. Ekbom A., Helmick C., Zack M., and Adami H.O. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 323 (1990) 1228-1233
17. Ahlquist D.A., Wieand H.S., Moertel C.G., McGill D.B., Loprinzi C.L., O'Connell M.J., et al. Accuracy of fecal occult blood screening for colorectal neoplasia. J. Am. Med. Assoc. 269 (1993) 1262-1267
18. Albataineh H., Kenkre C., Boda H., Zawadzki L., Iordanova V., Bowman J., and Tobi M. Is the reproducibility of native antigen binding by Adnab-9 antibody superior to that of DCC when used as a potential predictive marker for colorectal neoplasia?. Gastroenterology 124 (2003) A653
19. Srivastava S., Verma M., and Henson D.E. Biomarkers for early detection of colon cancer. Clin. Cancer Res. 7 (2001) 1118-1126
20. Haber M.M. Histological precursors of gastrointestinal tract malignancy. Gastroenterol. Clin. North Am. 31 (2002) 395-419